{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Port Therapeutics, Inc. (\"Port\"). Port incorporated in Delaware and is presently headquartered in Los Angeles, California.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2024/01/09/2024-00209.html","cfr_references":[],"citation":"89 FR 1107","comment_url":null,"comments_close_on":"2024-01-24","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 24, 2024 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2024-00209","effective_on":null,"end_page":1108,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2024/01/09/2024-00209.xml","html_url":"https://www.federalregister.gov/documents/2024/01/09/2024-00209/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-thermally","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2024-00209?publication_date=2024-01-09","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2024-01-09/2024-00209/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":144,"last_updated":"2026-10-22 14:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-01-09/pdf/2024-00209.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-00209.pdf?1704721520","publication_date":"2024-01-09","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2024/01/09/2024-00209.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2024-01-09T09:10:06Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":1107,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of Thermally Responsive T Cell Therapies for the Treatment of HPV-Positive Cancer(s)","toc_doc":"Development and Commercialization of Thermally Responsive T Cell Therapies for the Treatment of HPV-Positive Cancer(s)","toc_subject":"Licenses; Exemptions, Applications, Amendments etc.:\n","topics":[],"type":"Notice","volume":89}